Of all the industrialized countries of the world, Japan has the highest rate of hepatitis C. It also has 1 of the oldest and most varied histories of hepatitis C in the world among the industrialized modern nations. Hepatitis C and its complications are the leading cause of liver cancer in Japan. Japan has the highest rate of liver cancer among the industrialized countries. From 2004 to 2014, PegIFN/RBV treatment was the mainstream of hepatitis C treatment. In 2014, the first interferon-free therapy was approved in Japan. Subsequently, other interferon-free therapies have been approved. Hepatitis C virus disinfection in hepatitis C patients in Japan has become possible with a probability of 96% or more.
HISTORY OF HCV IN JAPAN
Alan Franciscus, who is the editor in chief of the hepatitis C virus (HCV) Advocate website, introduced the history of HCV in Japan. 1 Modern medicine and public health came early to Japan in the late 1800s. In the early 1900s, the discovery of the hypodermic needle and a drug to treat schistosomiasis would transmit hepatitis C throughout Japan. Schistosomiasis is a disease caused by a worm that lives in water snails. When people wade in water for agricultural work, the worm enters their body and lays eggs. The eggs hatch and travel to the liver. Schistosomiasis causes damage to the liver, the gastrointestinal system, kidneys, and genitals. It can, over time, cause death. In some parts of the world, it is considered as deadly as malaria. The first treatment developed to treat schistosomiasis consisted of multiple intravenous injections of antimony sodium tartrate. By the 1970s there were approximately 10 million intravenous injections given to people in Japan. 2, 3 The treatment of schistosomiasis was the beginning of the HCV epidemic in Japan. The injections were given with used or unsterile hypodermic needles. Nagai Nagyoshi discovered methamphetamine in 1893. Dr. Ogata Akira was able to synthesize it into crystalline meth in 1919. Widespread use of methamphetamine use did not begin until World War l, when it was used as an injectable treatment for asthma.
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The large-scale use came later during World War II, when it was prescribed as an oral and injectable stimulant for tired soldiers, pilots, and ammunition workers during the war. After the war methamphetamine was prescribed for general postwar trauma. In 1949, Japan banned the manufacture of methamphetamine, but illegal methamphetamine use continued as did the hepatitis C epidemic. 4 
CURRENT STATUS OF HCV INFECTION IN JAPAN
Of all the industrialized countries of the world, Japan has the highest rate of hepatitis C (caused by HCV). It also has 1 of the oldest and most varied histories of hepatitis C in the world among the industrialized modern nations. Hepatitis C and its complications are the leading causes of liver cancer in Japan. Japan has the highest rate of liver cancer among the industrialized countries. Hepatitis C virus is the 4th leading cause of death among Japanese men and the 5th leading cause of mortality among Japanese women. Of the 1.2 million people living with HCV infection in Japan, approximately 70% have HCV genotype 1b and 30% have genotype 2a/b. Further, a significant number of patients with HCV infection in Japan are over the age of 65, leading to more disease-related complications and a decreased likelihood of tolerating interferon-based therapies, the historical standard of care for treating HCV. Japan has a multilayered health care system. Many people can get health care insurance through their employer or the national health care system. The government system covers about 70% and the patient covers the remaining 30%. The HCV disinfection in hepatitis C patients in Japan has become possible with a probability of 96% or more.
PROGRESS AND FUTURE OF HEPATITIS C THERAPY IN JAPAN
DACLATASVIR AND ASUNAPREVIR COMBINATION THERAPY FOR HCV1 IN JAPAN
All oral combinations of direct-acting antivirals may improve the efficacy and safety outcomes for patients with HCV infection, particularly those who are poor candidates for interferon/ribavirin-based regimens.
In The most common adverse events were nasopharyngitis (29.2%), headache (7.0%), and malaise (5.3%) in patients receiving ledipasvir-sofosbuvir, and nasopharyngitis (23.5%), anemia (13.5%), and headache in those receiving ledipasvir-sofosbuvir plus RBV (8.8%). They concluded that the efficacy, tolerability, and absence of drug-drug interactions of ledipasvir-sofosbuvir suggest that it could be an important option for the treatment of genotype 1 HCV in Japanese patients.
